Peripheral blood CD8+ T-cell count at diagnosis predicts prognosis in R-CHOP-treated diffuse large B-cell lymphoma patients.
Baseline immune cell counts help predict treatment outcomes in lymphoma, potentially guiding therapy selection.
Baseline peripheral blood CD8+ T-cell count at diagnosis is an independent prognostic factor for outcomes in R-CHOP-treated DLBCL patients. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective cohort
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Ann Hematol
Why it surfaced
Clinically practical CBC-accessible immune biomarker for DLBCL prognosis, potentially implementable in routine practice without specialized assays.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.